| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
45,645 |
38,870 |
$2.30M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
28,557 |
23,306 |
$865K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
28,004 |
22,755 |
$800K |
| 36475 |
|
2,719 |
1,628 |
$658K |
| 64493 |
|
8,036 |
5,927 |
$358K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
16,120 |
13,488 |
$269K |
| 64635 |
|
2,615 |
2,018 |
$262K |
| 93971 |
|
4,203 |
3,297 |
$235K |
| 93970 |
|
2,437 |
2,221 |
$232K |
| 64483 |
|
3,827 |
2,576 |
$213K |
| 01938 |
|
4,753 |
3,194 |
$192K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,415 |
2,884 |
$190K |
| 64494 |
|
8,041 |
5,923 |
$189K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
13,289 |
3,311 |
$178K |
| 64636 |
|
3,661 |
2,001 |
$174K |
| 64495 |
|
5,827 |
4,136 |
$146K |
| 98940 |
|
14,719 |
3,896 |
$138K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,082 |
991 |
$106K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,028 |
1,685 |
$99K |
| 36465 |
|
92 |
70 |
$73K |
| 27096 |
|
953 |
831 |
$57K |
| 01940 |
|
1,135 |
797 |
$52K |
| 20610 |
|
2,011 |
1,651 |
$47K |
| 97014 |
|
10,260 |
2,341 |
$44K |
| 01937 |
|
1,184 |
770 |
$44K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
407 |
378 |
$41K |
| 64490 |
|
851 |
484 |
$23K |
| 36471 |
|
766 |
540 |
$21K |
| 99442 |
|
2,954 |
2,519 |
$20K |
| 77002 |
|
1,533 |
1,272 |
$19K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
1,373 |
388 |
$18K |
| 62323 |
|
620 |
401 |
$17K |
| 01160 |
|
214 |
201 |
$12K |
| 64491 |
|
826 |
464 |
$12K |
| 62321 |
|
290 |
216 |
$11K |
| 01992 |
|
186 |
154 |
$11K |
| 99152 |
|
770 |
505 |
$10K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
3,487 |
718 |
$8K |
| 36470 |
|
468 |
315 |
$7K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
110 |
80 |
$3K |
| 76942 |
|
299 |
170 |
$3K |
| 64492 |
|
471 |
210 |
$3K |
| 01939 |
|
55 |
39 |
$2K |
| 64633 |
|
58 |
30 |
$2K |
| 64634 |
|
106 |
30 |
$2K |
| 20552 |
|
46 |
43 |
$1K |
| 77003 |
|
115 |
58 |
$1K |
| 64484 |
|
173 |
95 |
$1K |
| 36482 |
|
28 |
27 |
$897.22 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
330 |
273 |
$887.63 |
| 01200 |
|
13 |
12 |
$568.91 |
| 01942 |
|
23 |
12 |
$391.06 |
| 20605 |
|
18 |
15 |
$145.28 |
| 99243 |
|
202 |
90 |
$0.00 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
331 |
66 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
2,500 |
1,375 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
4,519 |
1,957 |
$0.00 |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
34 |
16 |
$0.00 |
| G8942 |
Functional outcome assessment using a standardized tool is documented within the previous 30 days and a care plan, based on identified deficiencies is documented within two days of the functional outcome assessment |
755 |
141 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
1,198 |
439 |
$0.00 |